Understanding Multiple Myeloma: Symptoms, Diagnosis, and Treatment Advances

Dave entered his annual physical without major health concerns, but a routine exam revealing anemia, followed by a bathroom fall and fracture, led to a diagnosis of multiple myeloma—an aggressive blood cancer developing in bone marrow plasma cells. Nearly all patients eventually experience relapse, moving through complex treatment paths with therapies like BLENREP.

When Dave received his diagnosis following a bone fracture and routine blood work, he joined approximately 36,000 new patients expected to be diagnosed with multiple myeloma each year. More than half of these diagnoses occur in men, and the majority affect individuals aged 65 and older. Because early symptoms like fatigue and bone pain are frequently attributed to normal aging, clinical discovery often happens incidentally during hospital visits for accidental fractures.

In Plain English: The Clinical Takeaway

• Multiple Myeloma: A malignancy of plasma cells in the bone marrow. When cancerous, these cells crowd out normal marrow elements and produce abnormally high levels of immunoglobulins (antibodies) that can clog the kidneys and destroy the bone.
• Relapse and Remission: Multiple myeloma is not a curable disease. Most patients cycle through periods of clinical remission followed by relapse, requiring treatment options as the disease returns.
• Targeted Antibody Therapeutics: Modern regimens utilize specialized delivery mechanisms to bind directly to specific proteins on cancer cells, delivering medicine from within while engaging the patient’s immune defenses.

Understanding the Pathology and Diagnostic Timeline

Normally, healthy plasma cells manufacture protective immunoglobulins. In patients with multiple myeloma, these cells multiply and produce abnormally high levels of immunoglobulins that accumulate in the bloodstream and can clog the kidneys and destroy the bone. Hakan Kaya, MD, a hematologic oncologist at Cancer Care Northwest in South Spokane, Washington, notes that these abnormal protein accumulations and the displacement of healthy marrow cause widespread clinical complications, most notably anemia.

Bone pain remains the hallmark clinical indicator, occurring in roughly 70 percent of newly diagnosed individuals. Persistent skeletal discomfort lasting for weeks or months requires medical attention. Additional warning signs encompass high calcium levels, frequent infections, bleeding or bruising easily, trouble breathing, and weakness in the arms or legs. Despite these indicators, the insidious onset means patients frequently attribute symptoms to their age or other reasons until an acute traumatic event, such as a fracture, prompts medical realization that something else is going on.

Therapeutic Evolution and Relapse Management

Following initial interventions, Dave underwent a series of treatments over several years. While initial protocols initially helped, the disease eventually stopped working, culminating in multiple relapses. These transitions frequently cause profound emotional distress, including anxiety and fear for what comes next.

Clinical consensus emphasizes that relapse is expected in the natural history of multiple myeloma. To combat refractory disease, regulatory agencies have approved specialized interventions. One such option is BLENREP (belantamab mafodotin-blmf) for injection 70 mg. Approved by the U.S. Food and Drug Administration (FDA), this prescription medicine is indicated in combination with bortezomib and dexamethasone for adults with multiple myeloma who have received at least two prior treatments, including a proteasome inhibitor and an immunomodulatory agent, and their cancer has come back or did not respond to prior treatment. The safety and efficacy of BLENREP in children remain unknown.

Describing the mechanism of action, Dr. Kaya characterizes the therapy as a molecular “Trojan horse.” The agent is engineered to attach specifically to BCMA, a protein expressed on multiple myeloma cells and some normal cells. Upon binding, the therapeutic complex internalizes, releasing medicine directly within the malignant cell, while simultaneously recruiting immune effector mechanisms to destroy the cancer from the exterior.

Clinical Parameter	Multiple Myeloma Overview
Annual Diagnoses	~36,000 new cases
Demographic Predominance	Over 50% in men; predominantly age 65 and older
Primary Symptom Prevalence	Bone pain present in 70% of newly diagnosed patients
Regulatory Status of Targeted Option	FDA-approved BLENREP in combination regimens for previously treated adults

Contraindications & When to Consult a Doctor

Patients considering advanced targeted therapies must understand the potential risks of BLENREP.

Individuals experiencing persistent, unyielding bone pain lasting longer than several weeks, unexplained fatigue, recurrent infections, or weakness in the arms or legs should immediately consult a doctor.

This article was sponsored by GSK.